Drugs / MLC901
MLC901
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05621590 | Mar 2020 → Aug 2022 | post-cardiac arrest syndrome | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07191028 | Aug 2026 → Feb 2029 expected | Alzheimer disease | Moleac Pte Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04861688 | Aug 2021 → Feb 2023 | traumatic brain injury | Moleac Pte Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04487275 | Aug 2018 → Sep 2020 | traumatic brain injury | Ali Amini Harandi | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03038035 Comparator | Dec 2016 → Jun 2018 | Alzheimer disease | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT01847924 Comparator | Mar 2013 → Apr 2018 | cognitive impairment with or without cerebellar ataxia | National University Hospital, Singapore | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-08-11 | Moleac Pte Ltd. | Results 𝗔𝗦𝗡𝗔 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 | 𝗕𝗮𝗹𝗶, 𝗜𝗻𝗱𝗼𝗻𝗲𝘀𝗶𝗮 | 𝟴 – 𝟭𝟬 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟬𝟮𝟱 moleac.com ↗
Dr. N. V. Ramani, Chair of the Asian Stroke Advisory Panel (ASAP), presented a poster on “Meta-Analysis of Effect of MLC601/MLC901 on Motor Recovery after Stroke”. |
| 2025-06-26 | Moleac Pte Ltd. | Results 🧠 NeuroAiD™II Shows Promising Results in Spinal Cord Injury Preclinical Study moleac.com ↗
NeuroAiD™II (MLC901) administration led to marked improvements in motor and sensory function, enhanced nerve conduction, axonal regeneration, and tissue preservation. |
| 2022-06-08 | Moleac Pte Ltd. | Results NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries moleac.com ↗
NeuroAiD was safe as add-on treatment in patients with severe SCI. |
| 2022-03-08 | Moleac Pte Ltd. | Results NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression moleac.com ↗
ATHENE study results support the benefit of NeuroAiD™II as a safe add-on therapy to standard AD treatment as the study found no evidence of a significant increase in adverse events between MLC901 and placebo. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-11 | Moleac Pte Ltd. | 𝗔𝗦𝗡𝗔 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 | 𝗕𝗮𝗹𝗶, 𝗜𝗻𝗱𝗼𝗻𝗲𝘀𝗶𝗮 | 𝟴 – 𝟭𝟬 𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟬𝟮𝟱 moleac.com ↗ |
| 2025-06-26 | Moleac Pte Ltd. | 🧠 NeuroAiD™II Shows Promising Results in Spinal Cord Injury Preclinical Study moleac.com ↗ |
| 2022-06-08 | Moleac Pte Ltd. | NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries moleac.com ↗ |
| 2022-03-08 | Moleac Pte Ltd. | NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression moleac.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLC 901 | “NEURoaid II (MLC 901) assessment in cognitively Impaired not demented subjects” NCT01847924 ↗7“MLC901 (NeuroAiD™II), a Traditional Chinese Medicine derived formulation” NCT07191028 ↗ |
| Known as | Neuroaid II | “MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components” NCT05621590 ↗4“Preclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD).” PMID 34856171 ↗ Nov 2021 “NEURoaid II (MLC 901) assessment in cognitively Impaired not demented subjects” NCT01847924 ↗ “MLC901 (NeuroAiD™II), a Traditional Chinese Medicine derived formulation” NCT07191028 ↗ “NeuroAiD II™ (MLC901) in Mild Traumatic Brain Injury” NCT04861688 ↗ |
| Known as | NeuroaidII (MLC901) | “Neuroaid II (MLC901)” NCT03038035 ↗1“NeuroaidII (MLC901)” NCT01847924 ↗ |
| Known as | NeuroAidTMII | “The MLC901 supplement that has been tested in the trial has a trade name NeuroAidTMII.” PMID 40638707 ↗ Jul 2025 |
| Modality | Traditional medicine (herbal / TCM) | “Traditional medicine MLC901 (NeuroAiD II) with neuroprotective and neuroproliferative properties in cellular and animal models of brain injury showed TBI-associated cognitive...” PMID 35418437 ↗ Apr 2022 |
| Route | Oral | “24 weeks intervention with orally MLC901. 2 capsules 3 times a day” NCT01847924 ↗ |